Hostname: page-component-7bb8b95d7b-lvwk9 Total loading time: 0 Render date: 2024-09-19T12:29:00.107Z Has data issue: false hasContentIssue false

Immunization against hepatitis B-what can we expect?: Results of a survey of antibody response to immunization in persons ‘at risk’ of occupational exposure to hepatitis B

Published online by Cambridge University Press:  15 May 2009

D. Westmoreland
Affiliation:
Department of Microbiology/Public Health Laboratory, Royal United Hospital, Combe Park, Bath
V. Player
Affiliation:
Department of Microbiology/Public Health Laboratory, Royal United Hospital, Combe Park, Bath
D. C. Heap
Affiliation:
Department of Occupational Health, Royal United Hospital, Combe Park, Bath
A. Hammond
Affiliation:
Department of Occupational Health, Royal United Hospital, Combe Park, Bath
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

One thousand three hundred and twenty adults at risk of occupational exposure to hepatitis B were immunized using genetically engineered surface antigen and their antibody response (anti-HBs IU/1) assessed. Sex was known for all subjects and age for 1120 (range from 17–71 years). Seven hundred and sixty-four subjects were immunized in the local Department of Occupational Health, the remainder mainly by general practitioners.

Analysis of ‘good responders’ (anti-HBs > 100 IU/1) according to age and sex showed that increasing age and male sex had independent adverse effects on the likelihood of developing a satisfactory level of antibody to HBsAg. Furthermore even those most likely to respond well (young women), had a 1/5 to 1/6 failure rate to achieve > 100 IU/1 anti-HBs.

Of 63 persons who received a fourth dose of vaccine, 26 developed anti-HBs titres > 100 IU/1 when tested after 6 months. Subjects who had a low level of anti-HBs following primary immunization were more likely to develop > 100 IU/1 anti-HBs following a booster dose than were non-responders (< 10 IU/1).

Type
Research Article
Copyright
Copyright © Cambridge University Press 1990

References

REFERENCES

1.Weidermann, G, Ambrosch, F, Kremsner, P et al. , Reactogenicity and immunogenicity of different lots of a yeast-derived hepatitis B vaccine. Postgrad Med J 1987; 63 (suppl 2): 109–12.Google Scholar
2.Scheiermann, N, Gesemann, KM., Kreuzfelder, E., Paar, D. Effects of a recombinant yeast-dried hepatitis B vaccine in healthy adults. Postgrad Med J 1987: 63 (suppl 2): 115–9.Google Scholar
3.Courouce-Pauty, AM, Naret, C, Cianeionni, C, Adhemar, JP, Soulier, JP. Prevention of viral hepatitis B in haemodialysis units by means of anti-HBS immunoglobulins. Transplant Clin Immunol 1978: 10: 7785.Google Scholar
4.Ambrosch, F, Frisch-Niggemeyer, W, Kremsher, P. et al. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J 1987; 63 (suppl 2): 129–35.Google ScholarPubMed
5.Hadler, SC., Francis, DP, Maynard, JE et al. , Long term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. New Engl J Med 1986; 315: 209–14.Google Scholar
6.Fagan, E., Williams, R., Eddleston, ALWF.Hepatitis B vaccine: responder status and timing of additional booster doses. Lancet 1987; II 561.CrossRefGoogle Scholar
7.Laplanche, A, Courouce, AM, Benhamou, E, Jungers, P. Timing of hepatitis B revaccination in healthy adults. Lancet 1987; I: 1206.CrossRefGoogle Scholar
8.Follet, EAC, Symington, IS, Cameron, MG. Experience with hepatitis B vaccination in nurses in a hospital for the mentally handicapped. Lancet 1987; II: 728–31.CrossRefGoogle Scholar
9.Hadler, SC. Are booster doses of hepatitis B vaccine necessary ? Ann Intern Med 1988; 108: 457–8.Google Scholar
10. Anonymous. Immunisation against hepatitis B. Lancet 1988; I: 875–6.Google Scholar
11.Pead, PJ. Immune responses to hepatitis B vaccination in hospital staff. Biomed Pharmacother 1986; 40: 251–3.Google Scholar
12.Pead, PJ, Saeed, AA., Hepatitis, Bvaccination: effect of re-vaccination and injection site in suboptimal responders. Eur J Epidemiol 1986; 2: 240–1.Google Scholar
13.Just, M, Berger, R, Just, V. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma derived vaccine in young adults. Postgrad Med J 1987; 63 (suppl 2): 121–3.Google Scholar
14.Prinsen, H, Goilav, C., Safary, A., Andre, FE, Piot, P. Immunogenicity and tolerance of a yeast derived hepatitis vaccine in homosexual men. Postgrad Med J 1987; 63 (suppl 2): 147–50.Google Scholar
15.Bruguera, M., Cremades, M., Mayor, A., Sanchez, Tapias JM, Rodes, J. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Postgrad Med J 1987; 63 (suppl 2): 155–8.Google ScholarPubMed
16.Yvonnet, B., Coursaget, P, Chotard, J. et al. Hepatitis B vaccine in infants from an endemic area: Long term anti-HBS persistence and revaccination. J Med Virol 1987; 22: 315–21.CrossRefGoogle ScholarPubMed
17.Hsu, HM., Chen, DS., Chuang, CH et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. JAMA 1988; 260: 2231–5.Google Scholar
18.Fagan, EA., Tolley, P, Smith, H. et al. Hepatitis B vaccine: Immunogenicity and follow up including two year booster doses in high risk health care personnel in a London teaching hospital. J Med Virol 1987: 21: 4956.CrossRefGoogle Scholar
19.Fagan, EA., Williams, R.Hepatitis B vaccination Br J Clin Pract 1987; 41: 569–76.Google Scholar
20.Strickler, AC., Pavone, ED.Hepatitis B immunization: effect of 4th and 5th injections following suboptional seroconversion in health care workers. Can J Publ Health 1987; 78: 315–7.Google Scholar
21.Ukena, TE., Rosenkrantz, H., Bessette, HE, Esber, HJ. Immune response of hospital workers to hepatitis B vaccine. J Infect 1987; 14: 3941.Google Scholar
22.Tong, MJ, Howard, AM, Schatz, GC. et al. A hepatitis B vaccination program in a community teaching hospital. Infect Control Hosp Epidemiol 1987; 8: 102–7.CrossRefGoogle Scholar
23.Campbell, AD., Hambling, MH., Pinnington, PA, Lees, E. Efficacy of hepatitis B vaccine. J Soc Occup Med 1988; 38: 46–7.CrossRefGoogle ScholarPubMed
24.The Immunization Practices Advisory Committee. Center for Disease Control. Update on hepatitis B prevention. MMWR 1987; 36: 353–6.Google Scholar
25.Lunn, JA. Intradermal hepatitis B vaccine. Lancet 1989; I: 625.CrossRefGoogle Scholar
26.Goudeau, A., Denis, F, Mounier, M. et al. Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J 1987; 63 (suppl 2): 125–8.Google ScholarPubMed
27.Greenland, S., Robins, JM. Estimation of a common effect parameter from sparse follow up data. Biometrics 1985; 41: 5568.Google Scholar
28.Wismans, P., Van Hattum, J, Stelling, T., Poel, J, de-Gast, GC. Effect of supplementary vaccination in healthy non-responders to Hepatitis B vaccination. Hepatogastroenterology 1988; 35: 78–9.Google ScholarPubMed
29.Wheeley, SM, Boxall, EH, Tarlow, MJ. Prognosis of children who are carriers of hepatitis B. Br Med J 1987; 294: 211–3.Google Scholar